Guilherme Nader Marta/X
Jul 4, 2025, 18:03
Guilherme Nader Marta: We Break Down the Data and Its Implications of Inavolisib Triplet Approval
Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared on X:
“Inavolisib triplet approval marks real progress for patients with PIK3CA-mut HR+ mBC
With progress come new questions – on patient selection, toxicity and integration into practice
In this article we break down the data and its implications.”
Title: Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations
Authors: Guilherme Nader-Marta, Sara M. Tolaney, Erica L. Mayer
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 25, 2025, 03:39
Jul 24, 2025, 20:49
Jul 24, 2025, 20:37
Jul 24, 2025, 20:15
Jul 24, 2025, 20:05
Jul 24, 2025, 19:59
Jul 24, 2025, 19:29